
CLSA upgrades Tata Motors to ‘High Conviction Outperform’ citing JLR value, EV plans, and CV market growth. Discover their analysis…
CLSA upgrades Tata Motors to ‘High Conviction Outperform’ citing JLR value, EV plans, and CV market growth. Discover their analysis…
Motilal Oswal forecasts 60% upside for JSW Energy. Explore the rationale behind this bullish outlook!
Kotak boosts stakes in Zomato and Apollo Hospitals, removing United Spirits. Learn the reasons behind their strategy!
Market veteran Uday Kotak shares his thoughts on markets, FII selling and the potential impact of Trump tariff on Indian…
Kotak Institutional Equities raises the red flag on valuations. The latest report states that small and midcaps may see significant…
Chris Wood in the GREED & fear report highlights that the focus is on Ukraine, Gold and inflation as he…
Discover why Nomura picks M&M as top auto stock; potential 30% upside. Explore now!
Even as relentless FII selling continues, analysts believe that the Dollar Index holds the key to any potential trend reversal.…
Is the recent carnage in small and midcaps due to redemption pressure of SIPs in the smallcap and midcap funds…
The sentiment across the share market is significantly weak with investors worried about multiple fundamental and geo-political concerns. Here is…
Jefferies has picked Bharti Airtel as their preferred play in the telecom sector for a host of reasons. Here is…
Is there a hard stop for the markets? How can investors decide when the fall will begin to moderate. Analysts…
Fund managers are walking tight rope balancing investment rationale and distributor demands. Financial Express.com gets you select industry view on…
The top Index losers include key stocks. While many of these stocks have yielded hefty returns over 1-year, most of…
The markets are under pressure on US President Donald Trump’s latest tariff announcements, a weak currency and other reasons. A…
This is the first time in 5 years that expectations of rate cut is gathering momentum. That apart this RBI…
Jefferies maintains a Buy rating on JB Pharma citing strong CDMO growth potential and a 34% upside. Know more about…
FII selling resumes after a brief 1-day respite. Find out what it means for Indian markets going forward, in this…